3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
2
OTHER
1
Study Type
Observational
1
Interventional
1
Sponsor
Cancer Type
CNS
2
Conditions
Glioblastoma
472
Brain Neoplasms
306
Glioma
257
Neoplasms
122
Astrocytoma
88
Carcinoma, Non-Small-Cell Lung
76
Breast Neoplasms
70
Neuroblastoma
65
Central Nervous System Neoplasms
61
Melanoma
58
Recurrence
46
Lung Neoplasms
45
Pancreatic Neoplasms
41
Oligodendroglioma
37
Ovarian Neoplasms
36
Colorectal Neoplasms
36
Neoplasm Metastasis
33
Sarcoma
32
Medulloblastoma
28
Stomach Neoplasms
27
Gliosarcoma
27
Lymphoma
25
Prostatic Neoplasms
24
Head and Neck Neoplasms
24
Neurofibromatosis 1
23
Rhabdomyosarcoma
21
Neurofibroma, Plexiform
19
Esophageal Neoplasms
19
Diffuse Intrinsic Pontine Glioma
19
Cholangiocarcinoma
19
Interventions
Everolimus
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
INDUSTRY
×
Lymphangioleiomyomatosis
×
CNS
×
Clear all
NCT02654340
2023-02-10
TuScCom
CENTOGENE GmbH Rostock
Terminated
20 enrolled
NCT00790400
2017-02-17
EXIST-2
Novartis
Phase 3
Completed
118 enrolled
15 charts